title: Further Evidence for the Neuroplastic Role of Cannabinoids: A Study in Organotypic Hippocampal Slice Cultures.
abstract: Endocannabinoid receptors CB1R and CB2R are present in the CNS and modulate synaptic activity. By using an in vitro model, two concentrations of CB1R agonist ACEA at 0.5 and 5 μM doses and CB1R antagonist AM251 at 1 and 10 μM doses were administered in organotypic slice cultures of mouse hippocampus, and their effects on neurons and glial cells were analyzed at different time points. Exposure to low concentrations of ACEA (0.5 μM) did not seem to affect tissue organization, neuronal morphology, or glial response. In contrast, at a higher concentration of ACEA, many neurons in the dentate gyrus exhibited strong caspase-3 immunoreactivity. After treatment with AM251, we observed an increase in caspase-3 immunoreactivity and a downregulation of CB1R expression. Results show that long-term hippocampal slice cultures respond to both CB1R activation and inactivation by changing neuronal protein expression patterns. In the present study, we demonstrate that CB1R agonist ACEA promotes alterations in the neuronal cytoskeleton as well as changes in CB1R expression in organotypic hippocampal slice cultures, and that CB1R antagonist AM251 promotes neuronal death and astroglial reaction.
authors: Institute of Anatomy and Cell Biology, Center for Neuroscience, University of Freiburg, Freiburg, Germany. lauracaltana@gmail.com.|Cell Biology and Neuroscience Institute, School of Medicine, University of Buenos Aires, Paraguay 2155, 3rd floor, Buenos Aires, 1114, Argentina. lauracaltana@gmail.com.
authors: Laura Romina
authors: LR
authors: Caltana
authors: Institute of Anatomy and Cell Biology, Center for Neuroscience, University of Freiburg, Freiburg, Germany.
authors: Bernd
authors: B
authors: Heimrich
authors: Cell Biology and Neuroscience Institute, School of Medicine, University of Buenos Aires, Paraguay 2155, 3rd floor, Buenos Aires, 1114, Argentina.
authors: Alicia
authors: A
authors: Brusco
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002186:Cannabinoids / Q000378:metabolism*; D053148:Caspase 3 / Q000378:metabolism; D002478:Cells, Cultured; D003599:Cytoskeleton / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D001095:Arachidonic Acids; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C119325:arachidonyl-2-chloroethylamide; C103505:AM 251; D053148:Caspase 3
references: J Neurosci. 2004 Apr 14;24(15):3862-9
references: 15084667
references: Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
references: 2308954
references: Int J Obes (Lond). 2006 Apr;30 Suppl 1:S19-23
references: 16570100
references: Brain Res. 2000 Jan 10;852(2):398-405
references: 10678767
references: Curr Pharm Des. 2008;14(23):2279-88
references: 18781978
references: Brain. 2003 Jun;126(Pt 6):1252-70
references: 12764049
references: Science. 2007 May 25;316(5828):1212-6
references: 17525344
references: Neuron. 2010 Oct 6;68(1):113-26
references: 20920795
references: Neuroscience. 2007 Feb 23;144(4):1516-22
references: 17178196
references: Brain Res. 2007 Jan 12;1128(1):61-9
references: 17140550
references: J Neurosci. 2001 May 15;21(10 ):RC146
references: 11319244
references: Ann N Y Acad Sci. 2006 Aug;1074:514-36
references: 17105950
references: Handb Exp Pharmacol. 2005;(168):1-51
references: 16596770
references: Neuroimmunomodulation. 2007;14(6):281-6
references: 18287809
references: J Cell Physiol. 2012 Jan;227(1):250-8
references: 21412772
references: J Neurosci. 1999 Jun 1;19(11):4544-58
references: 10341254
references: Clin Neurosci Res. 2005;5(2-4):185-199
references: 18806886
references: J Neurosci. 2011 May 25;31(21):7700-14
references: 21613483
references: Pharmacol Biochem Behav. 1991 Nov;40(3):671-6
references: 1666926
references: J Neurosci. 2002 Nov 15;22(22):9771-5
references: 12427832
references: Handb Exp Pharmacol. 2005;(168):299-325
references: 16596779
references: Neuropharmacology. 2011 Mar;60(4):674-82
references: 21130785
references: J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33
references: 10336536
references: Annu Rev Physiol. 2009;71:283-306
references: 19575681
references: J Biol Chem. 2010 Jun 18;285(25):19002-11
references: 20410309
references: Brain Res. 2006 Apr 26;1085(1):163-76
references: 16566907
references: Mol Pharmacol. 2009 Mar;75(3):667-76
references: 19103761
references: Nat Rev Immunol. 2005 May;5(5):400-11
references: 15864274
references: Mol Cell Neurosci. 2008 Jul;38(3):374-80
references: 18499473
references: J Neurosci Methods. 2007 Oct 15;166(1):24-31
references: 17681378
references: Prog Neurobiol. 1999 Jul;58(4):315-48
references: 10368032
references: Mol Cell Neurosci. 2008 Aug;38(4):526-36
references: 18562209
references: Ann N Y Acad Sci. 2008 Oct;1139:450-7
references: 18991892
references: J Biol Chem. 2005 Mar 25;280(12):11413-21
references: 15657046
references: J Neurosci Methods. 1991 Apr;37(2):173-82
references: 1715499
references: Pharmacol Rev. 2006 Sep;58(3):389-462
references: 16968947
references: Neuromolecular Med. 2005;7(1-2):37-50
references: 16052037
references: Exp Neurol. 2006 Aug;200(2):438-59
references: 16631170
references: Curr Med Chem. 2008;15(14 ):1428-43
references: 18537620
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135